189 related articles for article (PubMed ID: 31574418)
61. The Effect of the UK Coordinating Centre for Cancer Research Anal Cancer Trial (ACT1) on Population-based Treatment and Survival for Squamous Cell Cancer of the Anus.
Downing A; Morris EJ; Aravani A; Finan PJ; Lawton S; Thomas JD; Sebag-Montefiore D
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):708-12. PubMed ID: 26188917
[TBL] [Abstract][Full Text] [Related]
62. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
[TBL] [Abstract][Full Text] [Related]
63. RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?
Herman JM; Thomas CR
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):8-10. PubMed ID: 23582245
[No Abstract] [Full Text] [Related]
64. Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
Satake H; Yoshino T; Sasaki T; Bando H; Yoda Y; Ikematsu H; Kojima T; Fuse N; Zenda S; Doi T; Kaneko K; Ohtsu A
Jpn J Clin Oncol; 2012 Sep; 42(9):861-4. PubMed ID: 22717459
[TBL] [Abstract][Full Text] [Related]
65. Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Kapp KS; Kapp DS; Stuecklschweiger G; Berger A; Geyer E
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):189-99. PubMed ID: 8270441
[TBL] [Abstract][Full Text] [Related]
66. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Zilli T; Schick U; Ozsahin M; Gervaz P; Roth AD; Allal AS
Radiother Oncol; 2012 Jan; 102(1):62-7. PubMed ID: 21993403
[TBL] [Abstract][Full Text] [Related]
67. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
Crehange G; Bosset M; Lorchel F; Dumas JL; Buffet-Miny J; Puyraveau M; Mercier M; Bosset JF
Dis Colon Rectum; 2007 Jan; 50(1):43-9. PubMed ID: 17089083
[TBL] [Abstract][Full Text] [Related]
68. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
Ben-Josef E; Moughan J; Ajani JA; Flam M; Gunderson L; Pollock J; Myerson R; Anne R; Rosenthal SA; Willett C
J Clin Oncol; 2010 Dec; 28(34):5061-6. PubMed ID: 20956625
[TBL] [Abstract][Full Text] [Related]
69. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.
Sparano JA; Lee JY; Palefsky J; Henry DH; Wachsman W; Rajdev L; Aboulafia D; Ratner L; Fitzgerald TJ; Kachnic L; Mitsuyasu R
J Clin Oncol; 2017 Mar; 35(7):727-733. PubMed ID: 27937092
[TBL] [Abstract][Full Text] [Related]
70. Chemoradiotherapy for anal cancer: are we as good as we think?
Martin D; Rödel C; Fokas E
Strahlenther Onkol; 2019 May; 195(5):369-373. PubMed ID: 30937508
[TBL] [Abstract][Full Text] [Related]
71. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal.
Huang K; Haas-Kogan D; Weinberg V; Krieg R
World J Gastroenterol; 2007 Feb; 13(6):895-900. PubMed ID: 17352019
[TBL] [Abstract][Full Text] [Related]
72. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial.
Kouloulias V; Plataniotis G; Kouvaris J; Dardoufas C; Gennatas C; Uzunoglu N; Papavasiliou C; Vlahos L
Am J Clin Oncol; 2005 Feb; 28(1):91-9. PubMed ID: 15685041
[TBL] [Abstract][Full Text] [Related]
73. Time-dose considerations in the treatment of anal cancer.
Constantinou EC; Daly W; Fung CY; Willett CG; Kaufman DS; DeLaney TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):651-7. PubMed ID: 9336145
[TBL] [Abstract][Full Text] [Related]
74. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
[TBL] [Abstract][Full Text] [Related]
75. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
[TBL] [Abstract][Full Text] [Related]
76. Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer.
Lerman J; Hennequin C; Etienney I; Abramowitz L; Goujon G; Gornet JM; Guillerm S; Aparicio T; Valverde A; Cattan P; Quéro L
Eur J Cancer; 2020 Dec; 141():143-151. PubMed ID: 33137590
[TBL] [Abstract][Full Text] [Related]
77. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
[TBL] [Abstract][Full Text] [Related]
78. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
79. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
80. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Voong KR; Rashid A; Crane CH; Minsky BD; Krishnan S; Yao JC; Wolff RA; Skibber JM; Feig BW; Chang GJ; Das P
Am J Clin Oncol; 2017 Dec; 40(6):555-560. PubMed ID: 26237193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
